Who is sponsoring NCT01995734?

NCT01995734 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT01995734?

Interventions in NCT01995734: Pasireotide long acting release formulation.

What condition does NCT01995734 study?

NCT01995734 studies Acromegaly.

Is NCT01995734 still recruiting?

NCT01995734 is currently approved for marketing. Last updated 29 December 2015.

Last reviewed 2015-12-29 · How we verify

NCT01995734: ACCESS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly

APPROVED FOR MARKETING Last updated 29 December 2015

What this trial tests

trial testing Pasireotide long acting release formulation in Acromegaly. Approved for marketing.

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Status	APPROVED FOR MARKETING
Study type	EXPANDED_ACCESS
Sites	37 locations across United States

Drugs / interventions tested

Pasireotide long acting release formulation — full drug profile →

Conditions studied

Acromegaly — all drugs for Acromegaly →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Acromegaly. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study is planned as an expanded treatment protocol to provide acromegalic patients for whom medical therapy is appropriate access to pasireotide LAR while regulatory approval for pasireotide is sought.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study.
Fleseriu M, Rusch E, Geer EB, ACCESS Study Investigators. · · 2017 · cited 40× · PMID 27896545 · DOI 10.1007/s12020-016-1182-4
Analgesic effect of long-acting somatostatin receptor agonist pasireotide in a patient with acromegaly and intractable headaches.
Lovato CM, Kapsner PL. · · 2018 · cited 10× · PMID 29925553 · DOI 10.1136/bcr-2017-219686
Patients with Acromegaly Presenting with Colon Cancer: A Case Series.
Gordon MB, Nakhle S, Ludlam WH. · · 2016 · cited 6× · PMID 28025627 · DOI 10.1155/2016/5156295
Successful debulking of plurihormonal pituitary macroadenoma with long-acting pasireotide and dopamine agonist combination therapy.
Jerkins TW, Jerkins RK, Franklin R. · · 2019 · cited 1× · PMID 30899469 · DOI 10.1002/ccr3.1961

Verify or expand the search:

Other recruiting trials for Acromegaly

Currently open trials in the same condition.

NCT07037420 — ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly · Phase 2 · recruiting
NCT05401084 — Diet in the Management of Acromegaly · NA · recruiting
NCT05131100 — Korean Regulatory Post Marketing Surveillance for Somavert · recruiting
NCT05964712 — Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional Study · recruiting
NCT03158090 — The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01995734 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 29 December 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01995734.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing